Cambridge Investment Research Advisors
RIGL icon

Cambridge Investment Research Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,199
Closed -$266K – 4045
2025
Q4 		$266K Buy
+6,199
New +$234K ﹤0.01% 3325

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors's RIGL Position: Q1 2026 in Review

Cambridge Investment Research Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 6,199 shares — an estimated $266K sold.

Cambridge Investment Research Advisors first reported a position in RIGL in Q4 2025 and held it in 1 quarter. The position peaked at $266K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Cambridge Investment Research Advisors reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 6,199 Rigel Pharmaceuticals shares in Q1 2026, an estimated $266K.
  • Cambridge Investment Research Advisors first reported a position in Rigel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Rigel Pharmaceuticals position peaked at $266K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.